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Case Report
Hepatitis Associated With Prothionamide for
Treatment of Multidrug-resistant Tuberculosis
Han-Lin Hsu,1 Kuan-Jen Bai,1 Yi-Chun Chiang,2,3 Shian-Jiun Lin,1 Ming-Chih Yu1*
Timely and intensive monitoring for, and management of, adverse effects caused by anti-tuberculosis
drugs are essential components of control programs for multidrug-resistant tuberculosis (MDR-TB). This
retrospective case series was conducted in northern Taiwan from January 2007 to December 2008 at Taipei
Medical University–Wan Fang Hospital, a 750-bed tertiary-care center and MDR-TB referral center. Hepatitis
associated with prothionamide was defined as the recurrence of hepatitis after a second prothionamide
treatment re-challenge. In total, 47 patients with MDR-TB enrolled in the Directly Observed Therapy,
Short Course–Plus Program were identified during the study period, and 44 (93.6%) were treated with
prothionamide. Seven of these 44 patients (15.9%) developed hepatitis after being treated with prothion-
amide concurrent with other anti-tuberculosis agents. Hepatitis associated with prothionamide occurred
in three of these seven patients (6.8%). In these three patients, hepatitis developed following treatment
with prothionamide for 28 days, 39 days or 45 days. Hepatitis developed rapidly after re-challenge with
prothionamide at 4 days, 4 days and 3 days, respectively. Liver function returned to the normal range after
cessation of prothionamide treatment for 19 days, 27 days or 28 days. Close monitoring of liver function
was necessary in MDR-TB patients who received prothionamide treatment.
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Multidrug-resistant tuberculosis (MDR-TB) is 
defined as resistance to, at a minimum, the anti-
tuberculosis drugs isoniazid and rifampicin.
Multidrug resistance severely compromises anti-
tuberculosis management, and MDR-TB is a
growing problem throughout the world. The 
laboratory-based Taiwan Surveillance of Drug
Resistance in TB program was established in 2003.
Surveillance has revealed that 5.3% (2004) and
4.0% (2005) of TB isolates were MDR-TB.1 The
World Health Organization has recommended 
a duration of at least 18 months for culture con-
version when treating for MDR-TB.2 Concerns
have been raised over the possibility of excessive
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adverse affects during long-term use of multidrug
regimens. Second-line anti-tuberculosis agents
used in treatment of MDR-TB have many known
side effects,3–10 for example, hepatitis is associated
with prothionamide or ethionamide. This condi-
tion occurs more frequently when prothionamide
treatment is combined with another second-line
anti-tuberculosis medication, para-aminosalicylic
acid.3,4,6,9,11,12 Furthermore, treatment with pro-
thionamide was the most likely cause of fatali-
ties in a previous study.6 The clinical course of
prothionamide-associated hepatitis has only been
described in a few cases in the literature.11,12 Here,
we report three cases of hepatitis associated with
prothionamide treatment for MDR-TB.
Case Report
This retrospective case series was conducted in
Taiwan from January 2007 to December 2008, at
the Taipei Medical University–Wan Fang Hospital,
a 750-bed tertiary-care center and MDR-TB referral
center. For the purposes of this study, hepatitis was
defined as an elevated aminotransferase level >
five times the upper limit of normal [aspartate
aminotransferase (AST) < 41 U/L; alanine amino-
transferase (ALT) < 40 U/L], with or without symp-
toms, or > three times upper limit of normal in
the presence of symptoms, or elevated total biliru-
bin > 2 mg/dL (normal range, 0.3–1.2 mg/dL).13
Hepatitis associated with prothionamide was de-
fined as hepatitis that re-occurred after prothion-
amide re-challenge.
A total of 47 patients with MDR-TB enrolled
into the Directly Observed Therapy, Short Course
(DOTS)–Plus program were monitored during
the study period. The mean age of the patients
was 50.5 ± 16.3 years. Forty-four of these patients
(93.6%) received prothionamide. Seven of these
44 patients (15.9%) developed hepatitis during
concurrent treatment with prothionamide and
other anti-tuberculosis agents (para-aminosalicylic
acid, isoniazid, or pyrazinamide). Among these
seven patients, three (3/44, 6.8%) met our defini-
tion of hepatitis associated with prothionamide.
Case 1
A 37-year-old man with MDR-TB, who weighed
77.0 kg received the following anti-tuberculosis
multidrug regimen: rifater (rifampicin 120 mg/
isoniazid 80 mg/pyrazinamide 250 mg, 5 tablets
daily), ethambutol (800 mg daily), streptomycin
(1.0 g daily), levofloxacin (750 mg once daily),
cycloserine (250 mg 3 times daily) and prothion-
amide (250 mg 3 times daily). Baseline AST, ALT,
total bilirubin, blood cell counts and serum crea-
tinine levels were within normal limits. Blood
specimens tested on day 28 of treatment revealed
AST 215 U/L, ALT 366 U/L and total bilirubin
0.47 mg/dL. The patient complained of a mildly
poor appetite during the office visit, and denied
a history of alcohol abuse and exposure to any
other hepatotoxic drug or toxin. Tests for hepatitis
B surface antigen (HBsAg), anti-hepatitis A virus
IgM, and anti-hepatitis C virus (HCV) were nega-
tive. On the same day, all anti-tuberculosis agents
were discontinued. Eighteen days later, the original
doses of ethambutol, streptomycin, levofloxacin
and cycloserine were resumed. The AST and ALT
levels gradually decreased thereafter. Eight days
later, the patient was treated with prothionamide
(250 mg 3 times daily). Unfortunately, AST and
ALT increased again from 34 U/L to 286 U/L and
from 39 U/L to 185 U/L, respectively, after 4 days.
Prothionamide was discontinued on the fourth
day of this second administration course. Nineteen
days after discontinuation of the second proth-
ionamide treatment, AST and ALT returned to
normal levels (Figure 1).
Case 2
A 53-year-old man with MDR-TB, who weighed
61.2 kg received the following anti-tuberculosis
multidrug regimen: levofloxacin (750 mg daily),
streptomycin (1.0 g daily), para-aminosalicylic
acid (2.5 g 4 times daily) and prothionamide
(250 mg 3 times daily). Baseline AST, ALT, total
bilirubin, blood cell counts and serum creatinine
levels were within normal limits. Blood spe-
cimens tested on day 39 of treatment revealed
AST 433 U/L, ALT 319 U/L and total bilirubin
1.32 mg/dL. Five days prior to the office visit, the
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patient described decreased appetite, general fa-
tigue, and multiple joint pain. The patient de-
nied a history of alcohol abuse and exposure to
any other hepatotoxic drug or toxin. Tests for
HBsAg and anti-hepatitis A virus IgM were nega-
tive, but anti-HCV was positive. The patient had
a history of hepatitis related to first-line anti-
tuberculosis agents. On the same day, all anti-
tuberculosis agents were discontinued with the
exception of streptomycin. Five days later, levo-
floxacin (750 mg daily) was resumed. Four days
later, prothionamide 250 mg three times daily
was resumed. Four days later, AST and ALT levels
had increased from 174 U/L to 885 U/L and from
186 U/L to 764 U/L, respectively. Prothionamide
and levofloxacin were stopped immediately. Lev-
ofloxacin (750 mg daily), para-aminosalicylic acid
(2.5 g 4 times daily), and cycloserine (250 mg
twice daily) were added sequentially to the ther-
apeutic regimen, and close monitoring revealed
that liver function improved gradually. Twenty-
seven days after cessation of prothionamide treat-
ment, AST and ALT levels returned to normal
(Figure 2).
Case 3
A 52-year-old man with MDR-TB, who weighed
59.2 kg received the following anti-tuberculosis
multidrug regimen: moxifloxacin (400 mg daily),
streptomycin (0.9 g daily), cycloserine (250 mg
twice daily) and prothionamide (250 mg twice
daily). Baseline AST, ALT, total bilirubin, blood
cell counts and serum creatinine levels were nor-
mal. Blood specimens tested on day 45 of treat-
ment revealed AST 409 U/L and ALT 215 U/L. The
patient made no complaints during the office
visit. The patient denied a history of alcohol abuse
and exposure to any other hepatotoxic drug or
toxin, but he did have diabetes mellitus. Tests for
HBsAg and anti-HCV were negative. On the same
day, all anti-tuberculosis agents were continued
with the exception of prothionamide. AST and
ALT levels gradually decreased thereafter. Fifteen
days later, prothionamide (250 mg twice daily)
was resumed. Three days later, AST and ALT 
levels had increased from 73 U/L to 346 U/L and
47 U/L to 118 U/L, respectively. Prothionamide
treatment was discontinued and AST and ALT lev-
els returned to normal after 28 days (Figure 3).
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Figure 1. Hepatitis developed in a 37-year-old man with
multidrug-resistant tuberculosis after 28 days of treatment
with a combination of prothionamide, rifater, ethambutol,
streptomycin, levofloxacin and cycloserine. Prothionamide
treatment was terminated immediately. Hepatitis recurred
at 4 days into a second prothionamide treatment regimen.
Liver function normalized 19 days after discontinuation of
prothionamide.
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Figure 2. Hepatitis developed in a 53-year-old man with
multidrug-resistant tuberculosis after 39 days of treatment
with a combination of prothionamide, streptomycin, lev-
ofloxacin and para-aminosalicylic acid. Prothionamide treat-
ment was terminated immediately. Hepatitis recurred at 
4 days into a second prothionamide treatment regimen.
Liver function normalized 27 days after discontinuation of
prothionamide.
Prothionamide was discontinued permanently
due to hepatitis in all three cases described.
Discussion
One of the major concerns about second-line
anti-tuberculosis agents to treat MDR-TB is their
potential adverse effects. Hepatitis is one of the
severe adverse effects associated with MDR-TB
treatment. The reported rates of hepatitis associ-
ated with second-line drug treatment in patients
with MDR-TB have varied considerably, and range
from 1.7% to 16.8% with a median time of
3.0–8.2 months into treatment.3–7 Hepatitis has
been reported to be more commonly associated
with ethionamide, prothionamide and para-
aminosalicylic acid treatment.3,6 Prothionamide
has been reported as the most likely factor re-
sponsible for fatal events.6 However, no previous
study has described in detail the clinical course
of hepatitis associated with prothionamide treat-
ment in patients with MDR-TB.
In our retrospective case series, seven patients
developed hepatitis (15.9%) during treatment
with prothionamide and other anti-tuberculosis
medications; however, prothionamide associated
with hepatitis was verified here in only three
(6.8%) patients. The failure of some of our pa-
tients to meet our definition of prothionamide-
associated hepatitis could have been because they
did not received prothionamide re-challenge at 
a later date. Although prothionamide-associated
hepatitis was confirmed in 6.8% of our patients,
the possibility of prothionamide-associated hepa-
titis could not be totally excluded in those patients
who failed to conform to our strict definition.
Prothionamide-associated hepatotoxicity has pre-
viously been reported to occur in 9.0–22.7% of
patients with TB and < 2% of those with MDR-
TB.6,11,12 However, these earlier studies were 
published before the advent of the DOTS-Plus
program, and the patients were typically lacking
re-challenge with prothionamide, and did not
conform to a strict definition for hepatitis. The
fact that hepatitis was strictly defined in our 
patient population and that face-to-face clinical
assessments were supervised under the DOTS-
Plus program make our study distinct. It would
be a reasonable assumption that development of
hepatitis is not infrequent in MDR-TB patients
who receive prothionamide treatment.
Prothionamide-associated hepatitis can occur
in patients with or without chronic hepatitis B or
C, and also with or without a history of hepatitis
related to first-line anti-tuberculosis agents. The
day of treatment when hepatitis occurred was ear-
lier than in previous studies,3–7,12 and it was on
days 28, 39 and 45 in the three cases described
here. The dose of prothionamide used for these
three patients ranged from 500 mg to 750 mg
daily, and the dose used in the treatment regimen
did not exceed the weight-base dosing (500 mg/
day for 33–50 kg, and 750 mg/day for 51–70 kg), as
recommended by the World Health Organization
in 2008.2 Our cases developed prothionamide-
associated hepatitis regardless of a history of
hepatitis B or C. In addition, this condition oc-
curred earlier during the treatment regimen than
previously reported, even when patients received
adequate dosing.
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Figure 3. Hepatitis developed in a 52-year-old man with
multidrug-resistant tuberculosis after 45 days of treatment
with a combination of prothionamide, moxifloxacin, strep-
tomycin and cycloserine. Prothionamide was terminated
immediately. Hepatitis recurred at 3 days into a second
prothionamide treatment regimen. Liver function normalized
28 days after discontinuation of prothionamide.
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In these three cases, hepatitis occurred shortly
after re-challenge with prothionamide (4 days, 
4 days and 3 days, respectively); however, a long
time period was required for liver function to be
normalized (19 days, 27 days and 28 days, respec-
tively). These findings should serve to remind
physicians to be careful when deciding on a sec-
ond round of prothionamide treatment, particu-
larly in patients with a suspicious history of
hepatitis related to prothionamide.
In conclusion, hepatotoxic effects of prothion-
amide might develop in MDR-TB patients with or
without chronic hepatic liver disease, at varying
times during treatment and with varying doses.
Judicious follow-up of the clinical condition and
close monitoring of liver function is warranted
in MTB-TB patients who are receiving prothion-
amide treatment.
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